We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 11,352.00 | 11,350.00 | 11,352.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.55 | 175.98B |
From Apr 2019 to Apr 2024
By Ian Walker
Pharmaceutical company AstraZeneca PLC (AZN.LN) said Thursday that Aspen Group's (APZ.AU) unit will buy the remaining rights to its anesthetic medicines for up to $766 million.
Following the initial deal entered into in June 2016--which saw Aspen Global Incorporated gain exclusive commercialization rights to the medicines in markets outside the U.S.--Aspen Global will now buy the remaining rights to Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.
It is paying an initial $555 million for the remaining rights to the intellectual property and manufacturing knowledge related to the anesthetic medicines, plus a further $211 million based on performance.
AstraZeneca said it will continue to manufacture and supply the medicines to Aspen Global during a transition period of up to five years.
Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
September 14, 2017 02:41 ET (06:41 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
